Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Garcia-Donas, J; Font, A; Perez-Valderrama, B; Virizuela, JA; Climent, MA; Hernando-Polo, S; Arranz, JA; Llorente, MD; Lainez, N; Villa-Guzman, JC; Mellado, B; del Alba, AG; Castellano, D; Gallardo, E; Anido, U; del Muro, XG; Domenech, M; Puente, J; Morales-Barrera, R; Perez-Gracia, JL; Bellmunt, J.

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

LANCET ONCOLOGY. 2017; 18(5): 672-681 Nº de citas: 47 [doi:10.1016/S1470-2045(17)30242-5]

Jimenez-Fonseca, P; Carmona-Bayonas, A; Lorenzo, MLS; Plazas, JG; Custodio, A; Hernandez, R; Garrido, M; Garcia, T; Echavarria, I; Cano, JM; Palomo, AR; Mangas, M; Declara, IM; Ramchandani, A; Visa, L; Viudez, A; Buxo, E; Diaz-Serrano, A; Lopez, C; Azkarate, A; Longo, F; Castanon, E; Bayona, RS; Pimentel, P; Limon, ML; Cerda, P; Llosa, RA; Serrano, R; Lobera, MPF; Alsina, M; Nuno, A; Gomez-Martin, C.

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

Gastric Cancer. 2017; 20(3): 465-474 Nº de citas: 20 [doi:10.1007/s10120-016-0639-8]

Puente, J; Grande, E; Medina, A; Maroto, P; Lainez, N; Arranz, JA.

Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting

Therapeutic Advances in Medical Oncology. 2017; 9(5): 307-318 Nº de citas: 53 [doi:10.1177/1758834017692779]

Gonzalez-Billalabeitia, E; Sepulveda, JM; Maroto, P; Aparicio, J; Arranz, JA; Esteban, E; Girones, R; Lopez-Brea, M; Mendez-Vidal, MJ; Pinto, A; Sastre, J; de Prado, DS; Terrasa, J; Vazquez, S; Powles, T; Beyer, J; Castellano, D; del Muro, XG; Spanish Germ Cell Canc Grp; Spanish Oncology Genitourinary Grp.

Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

European Urology Focus. 2017; 3(2-3): 280-286 [doi:10.1016/j.euf.2016.07.002]

Climent, MA; Torregrosa, MD; Vazquez, S; Girones, R; Arranz, JA.

Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?

CANCER TREATMENT REVIEWS. 2017; 55: 173-180 Nº de citas: 4 [doi:10.1016/j.ctrv.2017.03.007]

Rivera, F; Andres, R; Felip, E; Garcia-Campelo, R; Lianes, P; Llombart, A; Piera, JM; Puente, J; Rodriguez, CA; Vera, R; Virizuela, JA; Martin, M; Garrido, P.

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

Clinical & Translational Oncology. 2017; 19(4): 508-518 Nº de citas: 11 [doi:10.1007/s12094-016-1595-9]

Fernandez-Martinez, A; Pascual, T; Perrone, G; Morales, S; de la Haba, J; Gonzalez-Rivera, M; Galvan, P; Zalfa, F; Amato, M; Gonzalez, L; Prats, M; Rojo, F; Manso, L; Pare, L; Alonso, I; Albanell, J; Vivancos, A; Gonzalez, A; Matito, J; Gonzalez, S; Fernandez, P; Adamo, B; Munoz, M; Viladot, M; Font, C; Aya, F; Vidal, M; Caballero, R; Carrasco, E; Altomare, V; Tonini, G; Prat, A; Martin, M.

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

Oncotarget. 2017; 8(13): 21930-21937 Nº de citas: 20 [doi:10.18632/oncotarget.15748]

Lope, V; Martin, M; Castello, A; Casla, S; Ruiz, A; Baena-Canada, JM; Casas, AM; Calvo, L; Bermejo, B; Munoz, M; Ramos, M; de Juan-Ferre, A; Jara, C; Anton, A; Jimeno, MA; Lluch, A; Antolin, S; Garcia-Saenz, JA; Estevez, P; Arriola-Arellano, E; Gavila, J; Perez-Gomez, B; Carrasco, E; Pollan, M.

Physical activity and breast cancer risk by pathological subtype

Gynecologic Oncology. 2017; 144(3): 577-585 Nº de citas: 33 [doi:10.1016/j.ygyno.2016.12.014]

Salvador, J; Urtasun, JA; Duart, FJB; Garcia-Campelo, R; Carbonero, RG; Lianes, P; Llombart, A; Casado, DI; Piera, JM; Mateu, MM; Puente, J; Rivera, F; Rodriguez, CA; Virizuela, JA; Martin, M; Garrido, P.

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

Clinical & Translational Oncology. 2017; 19(3): 341-356 Nº de citas: 16 [doi:10.1007/s12094-016-1535-8]

Sharma, P; Retz, M; Siefker-Radtke, A; Baron, A; Necchi, A; Bedke, J; Plimack, ER; Vaena, D; Grimm, MO; Bracarda, S; Arranz, JA; Pal, S; Ohyama, C; Saci, A; Qu, XT; Lambert, A; Krishnan, S; Azrilevich, A; Galsky, MD.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

LANCET ONCOLOGY. 2017; 18(3): 312-322 Nº de citas: 1398 [doi:10.1016/S1470-2045(17)30065-7]

Jimenez, MM; Ferrandiz, AC; Urtasun, JA; Garcia-Campelo, R; Gonzalez-Flores, E; Quintela, ML; Mateu, MM; Sanchez, CAR; Bertran, AS; Sanchez, JMS; Garcia, RV; Echaburu, JAV; Palmer, MAS.

New clinical trials regulation in Spain: analysis of royal decree 1090/2015

Clinical & Translational Oncology. 2017; 19(3): 291-300 Nº de citas: 6 [doi:10.1007/s12094-016-1550-9]

de Andres, C; Fernandez-Paredes, L; Tejera-Alhambra, M; Alonso, B; Ramos-Medina, R; Sanchez-Ramon, S.

Activation of Blood CD3(+)CD56(+)CD8(+) T Cells during Pregnancy and Multiple Sclerosis

Frontiers in Immunology. 2017; 8: Nº de citas: 20 [doi:10.3389/fimmu.2017.00196]

Martin, M; Chan, A; Dirix, L; O'Shaughnessy, J; Hegg, R; Manikhas, A; Shtivelband, M; Krivorotko, P; Lopez, NB; Campone, M; Borrego, MR; Khan, QJ; Beck, JT; Vazquez, MR; Urban, P; Goteti, S; Di Tomaso, E; Massacesi, C; Delaloge, S.

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4)

ANNALS OF ONCOLOGY. 2017; 28(2): 313-320 Nº de citas: 165 [doi:10.1093/annonc/mdw562]

Perez-Gracia, JL; Sanmamed, MF; Bosch, A; Patino-Garcia, A; Schalper, KA; Segura, V; Bellmunt, J; Tabernero, J; Sweeney, CJ; Choueiri, TK; Martin, M; Fusco, JP; Rodriguez-Ruiz, ME; Calvo, A; Prior, C; Paz-Ares, L; Pio, R; Gonzalez-Billalabeitia, E; Hernandez, AG; Paez, D; Piulats, JM; Gurpide, A; Andueza, M; de Velasco, G; Pazo, R; Grande, E; Nicolas, P; Abad-Santos, F; Garcia-Donas, J; Castellano, D; Pajares, MJ; Suarez, C; Colomer, R; Montuenga, LM; Melero, I.

Strategies to design clinical studies to identify predictive biomarkers in cancer research

CANCER TREATMENT REVIEWS. 2017; 53: 79-97 Nº de citas: 87 [doi:10.1016/j.ctrv.2016.12.005]

Echavarria, I; Granja, M; Bueno, C; Lopez-Tarruella, S; Peinado, P; Sotelo, M; Jerez, Y; Moreno, F; Torres, G; Lobo, M; Marquez-Rodas, I; Del Monte-Millan, M; Martin, M; Garcia-Saenz, JA.

Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2017; 162(1): 181-189 Nº de citas: 13 [doi:10.1007/s10549-016-4098-z]

Sharma, P; Lopez-Tarruella, S; Garcia-Saenz, JA; Ward, C; Connor, CS; Gomez, HL; Prat, A; Moreno, F; Jerez-Gilarranz, Y; Barnadas, A; Picornell, AC; del Monte-Millan, M; Gonzalez-Rivera, M; Massarrah, T; Pelaez-Lorenzo, B; Palomero, MI; del Val, RG; Cortes, J; Rivera, HF; Morales, DB; Marquez-Rodas, I; Perou, CM; Wagner, JL; Mammen, JMV; McGinness, MK; Klemp, JR; Amin, AL; Fabian, CJ; Heldstab, J; Godwin, AK; Jensen, RA; Kimler, BF; Khan, QJ; Martin, M.

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

CLINICAL CANCER RESEARCH. 2017; 23(3): 649-657 Nº de citas: 113 [doi:10.1158/1078-0432.CCR-16-0162]

Wapnir, IL; Gelber, S; Anderson, SJ; Mamounas, EP; Robidoux, A; Martin, M; Nortier, JWR; Geyer, CE; Paterson, AHG; Lang, I; Price, KN; Coates, AS; Gelber, RD; Rastogi, P; Regan, MM; Wolmark, N; Aebi, S.

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

ANNALS OF SURGICAL ONCOLOGY. 2017; 24(2): 398-406 Nº de citas: 27 [doi:10.1245/s10434-016-5571-y]

D'Angelo, SP; Larkin, J; Sosman, JA; Lebbe, C; Brady, B; Neyns, B; Schmidt, H; Hassel, JC; Hodi, FS; Lorigan, P; Savage, KJ; Miller, WH; Mohr, P; Marquez-Rodas, I; Charles, J; Kaatz, M; Sznol, M; Weber, JS; Shoushtari, AN; Ruisi, M; Jiang, J; Wolchok, JD.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

JOURNAL OF CLINICAL ONCOLOGY. 2017; 35(2): 226 Nº de citas: 500 [doi:10.1200/JCO.2016.67.9258]